Dr. Mathew Hall on the Impact of PSA Screening Recommendations

Video

In Partnership With:

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

In 2012 The US Preventive Services Task Force (USPSTF) finalized a recommendation that stated that PSA screening was unnecessary in all men. To determine if this recommendation is correct, Hall and his team measured PSA in National Comprehensive Cancer Network (NCCN) risk groups of men diagnosed with prostate cancer.

Their study looked at data from 2005 to 2013 on age, race, PSA, Gleason score, t-stage, and presence or absence of metastatic disease. The data analyzed came from 87,500 men from cancer centers throughout the country.

They found that prior to 2011 there was a slow but significant decline in the number of men with prostate cancer diagnosed with a PSA score greater than 10. After 2011, when the USPSTF recommendation was first introduced, this percentage increased at 3% per year.

Related Videos
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD